aiwiki.page
English
Health / Human Body & Physiology / renin-angiotensin-system

Renin–Angiotensin System

The renin–angiotensin system is a hormonal and tissue-signaling network that regulates blood pressure, fluid balance, kidney function, and cardiovascular remodeling.

30 keywords3 linked from11 not yet writtenWritten by AI
KidneyRenin–angiotensi…HomeostasisHypertensionInflammationFibrosisHypothalamusBrainRenin–Angi…

The renin–angiotensin system (RAS) is a network of enzymes, peptide messengers, and receptors that helps regulate arterial blood pressure, sodium balance, and extracellular fluid volume. Its classical circulating pathway begins when the kidney releases renin, an enzyme that initiates the production of angiotensin II. This peptide constricts blood vessels, changes renal sodium handling, and stimulates aldosterone secretion. Together with its aldosterone-dependent effects, the pathway is commonly described as the renin–angiotensin–aldosterone system (RAAS). The terms overlap, although “renin–angiotensin system” also encompasses tissue pathways and peptide actions that do not depend on aldosterone.

The system is essential to circulatory homeostasis during salt depletion, blood loss, and reduced kidney perfusion. Persistent or inappropriate activation contributes to hypertension, heart failure, and progressive kidney injury. Its importance extends beyond vascular constriction: angiotensin signaling influences thirst, autonomic activity, cellular growth, inflammation, and fibrosis. Drugs targeting different steps in the pathway have consequently become central to cardiovascular and renal medicine.

The familiar linear cascade is only part of the system. Alternative enzymes generate and degrade several biologically active angiotensin peptides, while receptors and local tissue environments determine their effects. Understanding the RAS therefore requires distinguishing circulating hormone concentrations from tissue signaling, short-term compensatory responses from chronic disease mechanisms, and experimentally demonstrated pathways from established clinical applications.

Discovery and development of the concept

The experimental origins of the RAS date to 1898, when Robert Tigerstedt and Per Bergman reported that extracts of rabbit kidney increased blood pressure in other rabbits. They named the pressor substance “renin.” Their preparation did not distinguish the enzyme from the products generated after its injection, but it established that the kidney could influence circulation through a blood-borne mechanism rather than solely through nerves or fluid excretion.

A second major development came in 1934, when Harry Goldblatt and colleagues produced sustained hypertension in dogs by constricting the renal arteries. These experiments connected reduced renal perfusion with elevated systemic pressure and provided a model of renovascular hypertension. The kidney receiving inadequate blood flow could initiate a response that raised pressure throughout the circulation, even when the resulting systemic pressure was excessive for other organs.

During the late 1930s and early 1940s, groups led by Eduardo Braun-Menéndez in Argentina and Irvine Page in the United States independently characterized a pressor substance generated through the action of renin on a plasma substrate. The Argentine group called it “hypertensin,” whereas Page and colleagues used “angiotonin.” The name “angiotensin,” adopted in 1958, combined elements of both terms. Subsequent biochemical work distinguished angiotensin I from angiotensin II and established the enzymatic conversion between them. The discovery of aldosterone in the early 1950s added an adrenal component to the physiological framework.

Work on angiotensin-converting enzyme also connected the pathway with the breakdown of bradykinin, a vasodilator peptide. Studies of bradykinin-potentiating peptides from the venom of the Brazilian pit viper Bothrops jararaca, including work by Sérgio Henrique Ferreira, helped establish the feasibility of enzyme inhibition. The development of orally active captopril in the 1970s, followed by its approval in the United States in 1981, transformed the RAS from a physiological model into a major therapeutic target.

Later discoveries expanded the original endocrine model. Angiotensin receptors were divided into distinct subtypes, locally expressed components were identified in numerous organs, and angiotensin-converting enzyme 2 was described in 2000. These findings did not replace the classical cascade; they showed that its effects depend on competing metabolic routes, receptor distribution, and tissue context. Modern descriptions therefore treat the RAS as an interacting network rather than a single sequence ending with vasoconstriction.

Molecular components and peptide processing

Renin is an aspartyl protease synthesized mainly by granular cells associated with the afferent arterioles of renal glomeruli. It is initially produced as preprorenin and then prorenin; removal of the prosegment produces active renin. Both renin and prorenin can enter the circulation, but active renin is responsible for the tightly regulated initiating cleavage of the classical endocrine pathway. Unlike angiotensin II, renin is principally an enzyme rather than a receptor-activating pressor peptide.

Its substrate, angiotensinogen, is a glycoprotein produced predominantly by the liver. Renin removes a ten-amino-acid peptide, angiotensin I, from its amino-terminal region. Angiotensin I has relatively little direct biological activity in the classical pathway. Angiotensin-converting enzyme (ACE), a zinc-dependent peptidase, removes its terminal dipeptide to form the eight-amino-acid angiotensin II. The principal sequence is:

Angiotensinogen→reninangiotensin I→ACEangiotensin II.\text{Angiotensinogen} \xrightarrow{\text{renin}} \text{angiotensin I} \xrightarrow{\text{ACE}} \text{angiotensin II}.

ACE is abundant on vascular endothelial surfaces, including the extensive pulmonary capillary bed, but conversion is not confined to the lungs. The enzyme also occurs in other tissues and in soluble form. In addition to generating angiotensin II, it degrades bradykinin and other peptides. This dual activity explains why inhibiting ACE has effects that cannot be reproduced simply by blocking an angiotensin receptor.

Angiotensin II is rapidly metabolized, with a circulating lifetime measured in seconds to minutes. Aminopeptidases produce shorter peptides, including angiotensin III and angiotensin IV. Angiotensin III retains activity at angiotensin receptors and can contribute to adrenal and central nervous system responses. Angiotensin IV has distinct binding interactions, including with insulin-regulated aminopeptidase, but many proposed physiological functions remain more firmly established in experimental models than in clinical medicine.

Angiotensin-converting enzyme 2 (ACE2) is a related but functionally different enzyme. It removes a single terminal amino acid and can convert angiotensin II to angiotensin-(1–7). It can also convert angiotensin I to angiotensin-(1–9), which may undergo further processing. Neprilysin and other peptidases provide additional routes to angiotensin-(1–7), while enzymes such as chymase can generate angiotensin II independently of ACE in certain tissue settings. Consequently, blocking one enzyme does not necessarily eliminate all angiotensin production. Peptide abundance reflects the balance of substrate availability, enzyme activity, cellular compartment, and degradation, not simply the amount of renin released.

Regulation of renin secretion

The kidney integrates three major signals controlling renin release: pressure within the renal circulation, sodium chloride delivery to the macula densa, and sympathetic nerve activity. These signals usually converge during reduced effective circulating volume. Renin secretion rises during hemorrhage, salt depletion, or reduced renal perfusion and falls when volume and perfusion are restored. This arrangement makes the RAS a compensatory mechanism whose activation depends on what the kidney senses rather than on total body fluid volume alone.

The first input is often called the intrarenal baroreceptor mechanism. Reduced pressure and stretch in the afferent arteriole favor renin release from nearby granular cells. The process is intrinsic to the renal vascular apparatus and should not be confused with the arterial baroreceptor reflex arising in the carotid sinus and aortic arch. Changes in vascular wall mechanics and intracellular signaling contribute, although the pressure-sensing machinery is more complex than a single identified receptor.

The second input comes from the juxtaglomerular apparatus, where the macula densa of the distal nephron lies near the vascular pole of its own glomerulus. Macula densa cells detect luminal sodium chloride largely through the sodium–potassium–chloride cotransporter NKCC2. Reduced delivery promotes signaling involving cyclooxygenase-2 and prostaglandin E₂, which stimulates renin secretion. Higher sodium chloride delivery favors ATP- and adenosine-related signals that suppress renin. These pathways overlap with, but are not identical to, tubuloglomerular feedback controlling afferent arteriolar resistance and filtration.

The third major input is activation of beta-1 adrenergic receptors on renin-secreting cells by renal sympathetic nerves. This explains part of the renin-suppressing action of beta blockers. Within granular cells, cyclic AMP is an important stimulus for renin synthesis and secretion. Calcium has an unusual inhibitory role in this setting: increased intracellular calcium generally suppresses renin release, a pattern sometimes described as the “calcium paradox” of renin secretion.

Angiotensin II closes a negative-feedback loop by suppressing further renin release, directly through angiotensin receptors and indirectly through changes in pressure and sodium handling. Restoration of extracellular volume further reduces the initiating stimulus. Conversely, ACE inhibitors and angiotensin receptor blockers commonly increase measured renin because they interrupt this feedback. Renin concentration therefore cannot be interpreted independently of medication exposure. Potassium, posture, dietary sodium, time of sampling, and physiological stress also influence the measured state of the system, either directly or through associated adrenal, neural, and renal responses.

Receptor signaling and alternative axes

Most familiar actions of angiotensin II are mediated by the angiotensin II type 1 receptor, usually abbreviated AT₁. This is a seven-transmembrane G protein-coupled receptor expressed in vascular smooth muscle, adrenal cortex, kidney, heart, and nervous tissue. In vascular smooth muscle, activation commonly engages Gq/11 proteins, phospholipase C, inositol trisphosphate, and intracellular calcium release. The resulting increase in contractile activity narrows resistance vessels and can raise arterial pressure within seconds.

AT₁ signaling is not limited to contraction. It also activates protein kinases, influences transcription, and stimulates NADPH oxidases that generate reactive oxygen species. Depending on cell type and duration, these processes can promote hypertrophy, extracellular matrix deposition, inflammatory signaling, and altered endothelial function. Beta-arrestin recruitment both regulates receptor internalization and supports additional signaling pathways. The range of downstream responses helps explain why chronic angiotensin II exposure can change organ structure as well as vascular tone.

The angiotensin II type 2 receptor, AT₂, has a different distribution and signaling profile. It is prominent during fetal development and is expressed in selected adult tissues, with expression sometimes changing after injury. In many experimental settings, AT₂ signaling promotes nitric oxide-related vasodilation, sodium excretion, and effects opposing AT₁-mediated growth. It is nevertheless inaccurate to describe AT₂ as invariably protective: its actions depend on the tissue, developmental stage, disease model, and availability of interacting signaling molecules.

A further branch involves angiotensin-(1–7) and the Mas receptor. This pathway is often associated experimentally with vasodilation and reduced inflammatory or fibrotic signaling. Because ACE2 can both remove angiotensin II and generate angiotensin-(1–7), the ACE2–angiotensin-(1–7)–Mas axis is frequently presented as a counter-regulatory arm of the system. The model is useful, but it does not imply that every physiological response can be predicted from a simple ratio of angiotensin II to angiotensin-(1–7).

Prorenin and renin can also bind a protein known as the (pro)renin receptor, encoded by ATP6AP2. Binding has been investigated as a means of enhancing local enzymatic activity and initiating cellular signals. However, this protein also has essential functions associated with vacuolar proton pumps and cellular homeostasis that are not reducible to the circulating RAS. Experimental effects of disrupting it therefore cannot automatically be attributed to blocked angiotensin production. Such distinctions are particularly important when extending receptor findings from cultured cells or genetically altered animals to human disease.

Integrated control of circulation and fluid balance

The RAS acts on several timescales. Angiotensin II can raise vascular resistance rapidly, while renal sodium retention and changes in body fluid volume develop over hours to days. A simplified relation between circulatory variables is:

Mean arterial pressure−right atrial pressure≈cardiac output×systemic vascular resistance.\text{Mean arterial pressure}-\text{right atrial pressure} \approx \text{cardiac output}\times\text{systemic vascular resistance}.

Angiotensin II can influence both sides of this relationship: vasoconstriction increases resistance, whereas retained sodium and water can increase venous return and cardiac filling. The actual response depends on cardiac performance, autonomic reflexes, and the distribution of vascular constriction.

Within the kidney, angiotensin II constricts both afferent and efferent arterioles, with the balance depending on concentration and physiological conditions. At moderate activation, preferential support of efferent arteriolar resistance can help sustain glomerular capillary pressure when renal perfusion falls. Renal blood flow may nevertheless decrease. At higher levels, broader vasoconstriction and changes in the glomerular filtration apparatus can reduce filtration. Thus, angiotensin II does not invariably increase the glomerular filtration rate; its effects depend on the initial hemodynamic state and intensity of activation.

Angiotensin II also directly promotes sodium reabsorption along the nephron, including stimulation of the proximal tubular sodium–hydrogen exchanger NHE3. This reduces sodium delivery downstream and supports extracellular volume conservation. In the adrenal zona glomerulosa, AT₁ activation stimulates aldosterone synthesis and secretion. Aldosterone acts through the mineralocorticoid receptor in the distal nephron, increasing the activity of sodium-transport machinery, including epithelial sodium channels and the sodium–potassium pump. The associated electrical and transport changes facilitate potassium secretion.

Fluid conservation also involves the nervous system. Angiotensin II acts at brain regions that can detect circulating signals, including circumventricular organs, to promote thirst and facilitate vasopressin release. Vasopressin increases collecting-duct water permeability through aquaporin-2 trafficking. Angiotensin signaling also interacts with the hypothalamus, brainstem circuits, and sympathetic outflow. These actions coordinate behavior, water retention, and cardiovascular responses rather than operating as independent hormonal effects.

Several mechanisms restrain this sodium-retaining system. Natriuretic peptides released in response to cardiac stretch oppose renin and aldosterone secretion and promote sodium excretion. Increased arterial pressure normally increases renal sodium loss through pressure natriuresis. Nitric oxide, renal prostaglandins, and local vascular feedback further modify the response. Long-term blood pressure regulation therefore emerges from the interaction of the RAS with renal excretory capacity, nervous control, and other endocrine systems; it cannot be explained by plasma angiotensin II concentration alone.

Tissue systems, development, and genetic variation

Many organs contain some combination of angiotensinogen, processing enzymes, angiotensin receptors, and peptide-degrading enzymes. Local signaling has been studied extensively in the kidney, heart, blood vessels, adipose tissue, adrenal glands, and brain. In a tissue RAS, peptides may act on neighboring cells or within restricted cellular compartments rather than producing a readily measurable change in peripheral blood. Circulating and local pathways are nevertheless connected through the uptake of substrates and peptides.

The kidney illustrates this interaction particularly clearly. Angiotensinogen is synthesized in renal tissue, especially proximal tubular cells, while filtered or circulating components can also contribute under some conditions. Angiotensin II can accumulate in renal compartments through receptor-mediated uptake and local formation. Intrarenal peptide concentrations and receptor activity therefore need not parallel plasma measurements. Claims that a particular tissue contains a fully autonomous RAS require additional evidence, because detecting one enzyme or receptor does not establish that every step occurs locally at physiologically important rates.

In the central nervous system, the blood–brain barrier restricts access of circulating peptides to much of the brain. Circumventricular organs provide specialized sites where blood-borne angiotensin II can influence neural circuits, while local expression of RAS components supports additional signaling possibilities. Experiments link central angiotensin pathways to thirst, salt appetite, vasopressin release, and sympathetic regulation. The relative contributions of local synthesis and circulating input vary by region and experimental condition.

The RAS also has a developmental role that differs from its familiar adult pressure-regulating function. Rare biallelic pathogenic variants in AGT, REN, ACE, or AGTR1 can cause autosomal recessive renal tubular dysgenesis, characterized by severely impaired proximal tubular development and fetal renal dysfunction. Reduced fetal urine production can lead to oligohydramnios and consequent pulmonary and skeletal complications. These disorders demonstrate that an intact pathway is necessary for normal fetal renal development and perfusion, not merely for maintaining adult blood pressure.

More common genetic variation has been investigated as a contributor to differences in enzyme activity, hypertension susceptibility, and treatment response. The ACE insertion/deletion polymorphism, for example, is associated with variation in circulating ACE levels. Its relationship to complex clinical outcomes is less straightforward and has not made it a routine stand-alone test for selecting RAS-blocking treatment. Blood pressure and cardiorenal disease are highly polygenic and environmentally influenced. A variant associated with one component’s concentration does not by itself establish a clinically useful predictor of whole-system activity or drug benefit.

Roles in hypertension and cardiorenal disease

In hypertension, RAS activity may be excessive relative to sodium balance or renal perfusion even when circulating renin is not above a laboratory reference interval. Some forms are clearly renin-driven, particularly renal artery stenosis affecting renal perfusion. Others have low circulating renin because sodium retention and increased pressure suppress its release. Low-renin hypertension is therefore not evidence that angiotensin-related mechanisms are absent, but neither does it establish that tissue RAS activation is the principal cause.

Renovascular disease illustrates how a compensatory response can become maladaptive. A kidney downstream of an arterial narrowing may respond as though systemic pressure were inadequate, releasing renin and promoting vasoconstriction and sodium retention. The resulting elevation of arterial pressure can maintain perfusion beyond the narrowing while exposing other vascular beds to hypertension. When a functioning kidney depends heavily on angiotensin II-mediated efferent arteriolar constriction, interruption of that mechanism can substantially alter filtration. The effect depends on the distribution and severity of vascular disease and on the function of the other kidney.

In heart failure, reduced cardiac output and altered renal perfusion activate sympathetic and RAS responses. Although total body sodium and water may already be increased, the kidney can receive signals of reduced effective arterial filling. Further retention then contributes to congestion and edema, while vasoconstriction increases the resistance against which the heart pumps. Angiotensin II and aldosterone also participate in hypertrophy and fibrotic remodeling. These mechanisms help explain why chronic neurohormonal blockade improves outcomes in heart failure with reduced ejection fraction rather than merely lowering blood pressure.

In chronic kidney disease, elevated pressure within surviving glomeruli and altered angiotensin signaling can contribute to albumin leakage and progressive structural injury. RAS blockade can reduce intraglomerular pressure and albuminuria, particularly in proteinuric disease. An early change in filtration after treatment has a different mechanism from the long-term changes in disease progression: a modest initial decline can reflect reduced glomerular pressure rather than direct toxic injury. Clinical interpretation nevertheless depends on its magnitude and the accompanying hemodynamic and biochemical context.

The pathway is also important in kidney disease associated with diabetes mellitus, where metabolic injury, altered glomerular hemodynamics, and inflammatory and fibrotic processes interact. Conversely, disorders of aldosterone production need not arise from excessive renin. In primary aldosteronism, adrenal aldosterone secretion is inappropriate for sodium status and relatively independent of renin, which is usually suppressed. This distinction separates an adrenal driver of sodium retention from the secondary aldosterone response to upstream RAS activation.

Laboratory assessment and interpretation

The most frequently used laboratory measures are plasma renin activity, direct renin concentration, and aldosterone concentration. Plasma renin activity measures the rate at which angiotensin I is generated during an incubation under specified laboratory conditions. It therefore reflects enzymatic activity influenced by both renin and substrate availability. Direct renin concentration uses an immunoassay to measure renin protein. The two measurements are related but are not interchangeable, particularly at very low concentrations or during treatment with a direct renin inhibitor.

Aldosterone and renin are often interpreted together through the aldosterone-to-renin ratio, especially in the assessment of primary aldosteronism. A high ratio may result from increased aldosterone, strongly suppressed renin, or both. Its meaning depends on the absolute concentrations and the assay-specific units and thresholds. A ratio calculated using plasma renin activity cannot be directly substituted for one using direct renin concentration. Suppressed renin alone does not establish autonomous aldosterone secretion.

Sampling conditions matter because the RAS is physiologically responsive. Upright posture, sodium intake, volume status, potassium concentration, and time of day can change results. Hypokalemia can suppress aldosterone secretion, potentially obscuring an adrenal abnormality. Kidney function also affects interpretation. Different assays and laboratories use different reference intervals, and low-end assay performance can have a disproportionate influence when a ratio contains renin in the denominator.

Medication effects are especially important. Diuretics commonly stimulate renin through sodium and volume loss; ACE inhibitors and angiotensin receptor blockers increase renin by removing negative feedback. Beta blockers tend to suppress renin. Mineralocorticoid receptor antagonists alter sodium balance and feedback, often increasing renin. Aliskiren, a direct renin inhibitor, can increase measured renin concentration while decreasing plasma renin activity. Thus, an increase in the amount of renin detected does not necessarily mean an increase in its enzymatic effect.

Direct measurement of angiotensin peptides is technically demanding because these molecules are present at low concentrations and can be rapidly generated or degraded after sampling. Collection procedures, enzyme inhibition, processing time, and analytical method can materially alter results. Mass spectrometry can distinguish several peptide species, but specialized peptide profiles are not equivalent to routine measures of receptor signaling in individual organs. Proposed biomarkers of intrarenal activity, including urinary angiotensinogen, also require interpretation in light of filtration-barrier damage and protein excretion. No single blood or urine measurement captures the entire circulating and tissue network.

Pharmacological intervention and unresolved questions

Several drug classes interrupt the RAS at different points. ACE inhibitors, including captopril, enalapril, and lisinopril, reduce ACE-dependent angiotensin II formation and diminish bradykinin breakdown. Angiotensin receptor blockers, such as losartan, valsartan, and candesartan, selectively block AT₁ receptors without directly inhibiting ACE. Aliskiren inhibits renin’s catalytic activity. These mechanisms are distinct even when their blood-pressure effects overlap: receptor blockers do not prevent all angiotensin II production, and ACE inhibition does not block every tissue route of angiotensin II formation.

Mineralocorticoid receptor antagonists act downstream of angiotensin signaling. Spironolactone and eplerenone inhibit aldosterone-dependent receptor activation; finerenone is a nonsteroidal member of this class with demonstrated cardiorenal benefits in studied populations, including people with type 2 diabetes and chronic kidney disease. Sacubitril/valsartan combines an angiotensin receptor blocker with inhibition of neprilysin, thereby influencing natriuretic peptides and other peptide systems as well as angiotensin signaling. It exemplifies how RAS-directed therapy can be integrated with an opposing hormonal pathway.

Evidence from randomized controlled trials established benefits beyond uncomplicated hypertension. CONSENSUS, reported in 1987, demonstrated a survival benefit from enalapril in severe heart failure. The SOLVD treatment trial, reported in 1991, extended the evidence in symptomatic left ventricular systolic dysfunction. RENAAL and IDNT, both reported in 2001, demonstrated renal benefits of angiotensin receptor blockade in type 2 diabetes with nephropathy. PARADIGM-HF, reported in 2014, demonstrated improved outcomes with sacubitril/valsartan compared with enalapril in selected patients with heart failure and reduced ejection fraction.

More complete blockade is not necessarily better. Trials of combined ACE inhibitor and angiotensin receptor blocker therapy, including ONTARGET and VA NEPHRON-D, documented increased adverse renal events or hyperkalemia without sufficient additional clinical benefit in the populations studied. Mechanistically, RAS inhibition can reduce filtration pressure and potassium excretion. ACE inhibitors can also cause cough and, less commonly, angioedema, partly through altered peptide degradation. ACE inhibitors and angiotensin receptor blockers can disrupt fetal renal function during pregnancy, especially with later gestational exposure.

Research continues on selective receptor signaling, tissue-specific peptide metabolism, and therapeutic manipulation of ACE2 or angiotensin-(1–7). ACE2 also serves as a cell-entry receptor for SARS-CoV-2, linking the pathway to COVID-19 biology without making its enzymatic role identical to its viral receptor function. A persistent experimental challenge is distinguishing peptide concentrations from functional signaling: species differences, sample handling, receptor expression, and non-angiotensin functions of individual proteins can all change the interpretation of a result. Demonstrating that a pathway alters cultured cells or animal physiology remains a different evidentiary step from establishing that targeting it improves human clinical outcomes.